Stomach Neoplasms
📧 Sign up to get email alerts when something new happens for Stomach Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-28EMA Authorised: Herzuma (trastuzumab) — Celltrion Healthcare Hungary Kft.
Authorised status for Herzuma (trastuzumab) in the European market for stomach and breast neoplasms.
-
EMA approval · 2026-08-18EMA Authorised: Herwenda (trastuzumab) — Sandoz GmbH
Authorised trastuzumab product Herwenda by Sandoz GmbH for breast and stomach neoplasms in the EU.
-
EMA approval · 2026-08-11EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.
EMA authorises Kanjinti (trastuzumab) for indications including stomach and breast neoplasms.
-
EMA approval · 2026-07-08EMA Authorised: Trazimera (trastuzumab) — Pfizer Europe MA EEIG
Authorised status for Trazimera (trastuzumab) by Pfizer Europe MA EEIG in the EMA system for use in stomach and breast neoplasms.
-
EMA approval · 2026-04-28EMA Authorised: Dazublys (trastuzumab) — CuraTeQ Biologics s.r.o
Authorised monoclonal antibody therapy trastuzumab (Dazublys) for breast and stomach neoplasms in the EU.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-02EMA Authorised: Herceptin (trastuzumab) — Roche Registration GmbH
The EMA authorised Herceptin (trastuzumab) for stomach neoplasms and breast neoplasms. The marketing authorization holder is Roche Registrat…
-
EMA approval · 2026-02-03EMA Authorised: Trazimera (trastuzumab) — Pfizer Europe MA EEIG
The EMA has authorised Trazimera (trastuzumab) for stomach and breast neoplasms, with Pfizer Europe MA EEIG as the marketing authorization h…
-
EMA approval · 2025-07-11EMA Authorised: Capecitabine Teva (capecitabine) — Teva Pharma B.V.
EMA authorised Capecitabine Teva (capecitabine), a generic capecitabine product by Teva Pharma B.V., for multiple cancer indications, includ…